Stockscreener 앱 받기
18.78
5.36%
0.955
시장 영업 전:
14.99
-3.79
-20.18%
전일 마감가:
$17.82
열려 있는:
$17.46
하루 거래량:
18,991
Relative Volume:
0.03
시가총액:
$15.76M
수익:
-
순이익/손실:
$-12.25M
주가수익비율:
-0.0405
EPS:
-463.5156
순현금흐름:
$-10.77M
1주 성능:
-9.36%
1개월 성능:
+90.47%
6개월 성능:
+108.67%
1년 성능:
-33.75%
1일 변동 폭
$17.46
$18.90
1주일 범위
$17.14
$21.96
52주 변동 폭
$5.01
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
명칭
Quoin Pharmaceuticals Ltd Adr
전화
97299741444
주소
23 HATA'AS STREET, KFAR SABA
QNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
18.78 | 14.95M | 0 | -12.25M | -10.77M | -463.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Quoin Pharmaceuticals Ltd Adr 주식(QNRX)의 최신 뉴스
Wall Street analysts’ outlook for Quoin Pharmaceuticals Ltd ADR (QNRX) - setenews.com
US Stocks Mixed; Sea Shares Gain After Q3 ResultsMSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM) - Benzinga
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings By Investing.com - Investing.com Philippines
Zoetis (NYSE:ZTS) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Survey - Defense World
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Manila Times
Quoin Pharmaceuticals stock rises after positive pediatric trial data - Investing.com
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause - MSN
Quoin Pharmaceuticals stock rises after positive pediatric trial data By Investing.com - Investing.com UK
Quoin Pharmaceuticals announces FDA granted ODD to QRX003 - TipRanks
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Quoin Pharmaceuticals, Ltd.American Depositary Shares (Nasdaq:QNRX) Stock Quote | Pittsburgh Post-Gazette - FinancialContent
Quoin Pharmaceuticals (NASDAQ:QNRX) Receives Sell (E) Rating from Weiss Ratings - Defense World
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Quoin Pharmaceuticals. Ltd Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com India
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
Quoin Pharmaceuticals (QNRX) Stock Forecast and Price Target 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Quoin Pharmaceuticals sets terms for $6.5 million offering - Investing.com
Quoin Pharmaceuticals. Ltd Sponsored ADR Earnings and Revenue – NASDAQ:QNRX - TradingView
Quoin Pharmaceuticals Ltd Adr (QNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):